{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:02Z","timestamp":1792592342923,"version":"4.5.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies. While its clinical efficacy is well established, CAR T-cell therapy is frequently associated with severe immune-mediated toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), coagulopathy, and hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Increasing evidence suggests that endothelial dysfunction, hemostatic imbalance, and complement activation are key contributors to the pathogenesis of these complications. Substantial research efforts have focused on identifying circulating biomarkers capable of predicting toxicity onset and severity, as well as stratifying patients at risk for early non-relapse mortality. In this review, we summarize the current understanding of the pathophysiological mechanisms underlying early CAR T cell\u2013related toxicities, with particular emphasis on biomarkers of endotheliopathy and related pathways involved in their development. We focus on highlighting translational biomarkers with potential diagnostic, prognostic, and monitoring value that could be implemented in clinical practice to improve patient risk stratification, differential diagnosis, and therapeutic follow-up.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1699894","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:23:07Z","timestamp":1762150987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Endothelial dysfunction and hemostatic imbalance in CAR T-cell-associated toxicities: pathophysiological insights and the role of circulating biomarkers"],"prefix":"10.3389","volume":"16","author":[{"given":"Ana Bel\u00e9n","family":"Moreno-Casta\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gontzal","family":"Iraola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Mart\u00ednez-Cibri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil","family":"Albiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel-Nicol\u00e1s Marco","family":"Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Martinez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Diaz-Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050994","article-title":"Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development","volume":"13","author":"Moreno-Casta\u00f1o","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-94353-0","volume-title":"The EBMT\/EHA CAR-T cell handbook","author":"Kr\u00f6ger","year":"2022"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell Malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood advances"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory Malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014182","article-title":"Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Wang","year":"2025","journal-title":"Blood advances"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New\u00a0Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New\u00a0Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet (London England)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1289303","article-title":"CAR Immunotherapy for the treatment of infectious diseases: a systematic review","volume":"15","author":"Morte-Romea","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood advances"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26519","article-title":"Results of ARI-0001 CART19 cell therapy in patients with relapsed\/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease","volume":"97","author":"Ortiz-Maldonado","year":"2022","journal-title":"Am J Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014360","article-title":"Clinical impact of [18F]FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma","volume":"9","author":"Zugasti","year":"2025","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/ph17050591","article-title":"Change in neurocognitive function in patients who receive CAR-T cell therapies: A steep hill to climb","volume":"17","author":"Strongyli","year":"2024","journal-title":"Pharm (Basel Switzerland)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"New Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/jcm12196124","article-title":"Exploring CAR-T cell therapy side effects: mechanisms and management strategies","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7548","article-title":"Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells","volume":"368","author":"Zhou","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001466","article-title":"Blockade of AIM2 inflammasome or \u03b11-AR ameliorates IL-1\u03b2 release and macrophage-mediated immunosuppression induced by CAR-T treatment","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet (London England)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood advances"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood advances"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp Mol Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(87)90139-3","article-title":"Enhanced release of von Willebrand factor by human endothelial cells in culture in the presence of phorbol myristate acetate and interleukin 1","volume":"47","author":"Giddings","year":"1987","journal-title":"Thromb Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nm1351","article-title":"Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation","volume":"12","author":"Fiedler","year":"2006","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-09-0731","article-title":"VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP","volume":"113","author":"Schwameis","year":"2015","journal-title":"Thromb haemostasis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/ijms25010644","article-title":"The mechanisms of altered blood-brain barrier permeability in CD19 CAR T-cell recipients","volume":"25","author":"Pinto","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/116.6.1425","article-title":"A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate","volume":"116","author":"Heyes","year":"1993","journal-title":"Brain"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London England)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011896","article-title":"Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma","volume":"8","author":"Nie","year":"2024","journal-title":"Blood advances"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood advances"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J haematology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1635062","article-title":"Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome","volume":"16","author":"Campodonico","year":"2025","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood advances"},{"key":"B78","doi-asserted-by":"publisher","first-page":"29630","DOI":"10.1038\/s41598-024-81123-5","article-title":"Association of endotheliopathy with coagulofibrinolytic reactions and disseminated intravascular coagulation after trauma: a retrospective observational study","volume":"14","author":"Matsumoto","year":"2024","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.10.006","article-title":"Is there a link between endothelial dysfunction, coagulation activation and nitric oxide synthesis in preeclampsia","volume":"415","author":"Dusse","year":"2013","journal-title":"Clinica Chim Acta"},{"key":"B80","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2023","journal-title":"Br J haematology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood advances"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic Malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood marrow Transplant"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.03.021","article-title":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Bindal","year":"2024","journal-title":"J Thromb haemostasis: JTH"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/ijms21113886","article-title":"Anagnostopoulos A. A new era in endothelial injury syndromes: toxicity of CAR-T cells and the role of immunity","volume":"21","author":"Gavriilaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01912-w","article-title":"Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro","volume":"58","author":"Martinez-Sanchez","year":"2023","journal-title":"Bone marrow Transplant"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.334","article-title":"Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide","volume":"100","author":"Eissner","year":"2002","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00395-008-0733-0","article-title":"The role of inflammatory cytokines in endothelial dysfunction","volume":"103","author":"Zhang","year":"2008","journal-title":"Basic Res Cardiol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B92","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbmt.2007.10.008","article-title":"The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cooke","year":"2008","journal-title":"Biol Blood marrow Transplant"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1285898","article-title":"Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications","volume":"10","author":"Palomo","year":"2023","journal-title":"Front Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.03.005","article-title":"Vascular permeability changes involved in tumor metastasis","volume":"335","author":"Garc\u00eda-Rom\u00e1n","year":"2013","journal-title":"Cancer letters"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17029","article-title":"Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia","volume":"25","author":"Hong","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.ahjo.2021.100046","article-title":"Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases","volume":"9","author":"di Candia","year":"2021","journal-title":"Am Heart J plus: Cardiol Res practice"},{"key":"B98","doi-asserted-by":"publisher","first-page":"11028","DOI":"10.3390\/ijms252011028","article-title":"Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) levels are significantly associated with endothelial injury indices in CAR-T cell recipients","volume":"25","author":"Gavriilaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1186\/ar576","article-title":"Endothelial activation: intracellular signaling pathways","author":"Pober","year":"2002","journal-title":"Arthritis Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005898","article-title":"CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity","volume":"11","author":"Jess","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021915","article-title":"Novel functions for von Willebrand factor","volume":"144","author":"Atiq","year":"2024","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.924461","article-title":"Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/ijms26073218","article-title":"Cardiovascular biomarkers: tools for precision diagnosis and prognosis","volume":"26","author":"Netala","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02489-8","article-title":"The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation","volume":"60","author":"Muratore","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007381","article-title":"Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"6","author":"Nawas","year":"2022","journal-title":"Blood advances"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004812","article-title":"Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation","volume":"5","author":"Pe\u00f1a","year":"2021","journal-title":"Blood advances"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2478\/aite-2024-0018","article-title":"Endothelial activation and stress index score as a prognostic factor of cytokine release syndrome in CAR-T patients - A retrospective analysis of multiple myeloma and large B-cell lymphoma cohorts","volume":"72","author":"Tomasik","year":"2024","journal-title":"Archivum immunologiae therapiae experimentalis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-A cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood advances"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood advances"},{"key":"B113","doi-asserted-by":"publisher","first-page":"100025","DOI":"10.1016\/j.bvth.2024.100025","article-title":"EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy","volume":"1","author":"Gavriilaki","year":"2024","journal-title":"Blood vessels Thromb hemostasis"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.625","article-title":"Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma","author":"Goel","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B115","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.3390\/cancers15225443","article-title":"Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities","volume":"15","author":"de Boer","year":"2023","journal-title":"Cancers"},{"key":"B116","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/cancers17060918","article-title":"Addition of phosphorous and IL6 to m-EASIX score improves detection of ICANS and CRS, as well as CRS progression","volume":"17","author":"Barker","year":"2025","journal-title":"Cancers"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05477-y","article-title":"IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy","volume":"102","author":"Wang","year":"2023","journal-title":"Ann Hematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood advances"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; A review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.06.008","article-title":"A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy","volume":"25","author":"Zu","year":"2023","journal-title":"Cytotherapy"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02567-5","article-title":"Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary Malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee","volume":"60","author":"Ort\u00ed","year":"2025","journal-title":"Bone Marrow Transplantation"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284564","article-title":"Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic Malignancies","volume":"109","author":"Perl","year":"2024","journal-title":"Haematologica"},{"key":"B123","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/jpm13040688","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in autoimmune rheumatic and non rheumatic diseases","volume":"13","author":"Manfredi","year":"2023","journal-title":"J Pers Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001806","article-title":"Association of the circulating supar levels with inflammation, fibrinolysis, and outcome in severe burn patients","volume":"56","author":"Lin","year":"2021","journal-title":"Shock (Augusta Ga)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1182\/blood-2024-198872","article-title":"Association between post-CART terminal complement complex levels and immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"144","author":"Bezerra","year":"2024","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.TUMBODY-B048","article-title":"Abstract B048: Neutrophil extracellular traps-targeting DNase I enhances the therapeutic efficacy of CAR-T cell adoptive immunotherapy in a syngeneic murine metastasis model","volume":"84","author":"Stepanov","year":"2024","journal-title":"Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"15","DOI":"10.32607\/actanaturae.11503","article-title":"Neutrophil extracellular traps (NETs): opportunities for targeted therapy","volume":"13","author":"Volkov","year":"2021","journal-title":"Acta naturae"},{"key":"B130","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.1182\/blood-2023-179506","article-title":"Easix indices predict CRS and overall survival in adult CAR-T cell recipients","volume":"142","author":"Gavriilaki","year":"2023","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-022-00777-4","article-title":"Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma","volume":"13","author":"Acosta-Medina","year":"2023","journal-title":"Blood Cancer J"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro-oncology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.3390\/cancers17172876","article-title":"Endothelial injury following CAR-T cell immunotherapy for hematological Malignancies","volume":"17","author":"Demosthenous","year":"2025","journal-title":"Cancers"},{"key":"B134","doi-asserted-by":"publisher","first-page":"189155","DOI":"10.1016\/j.bbcan.2024.189155","article-title":"Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors","volume":"1879","author":"Wachholz","year":"2024","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138808","article-title":"CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth","volume":"5","author":"Zhuang","year":"2020","journal-title":"JCI Insight"},{"key":"B136","doi-asserted-by":"publisher","first-page":"188701","DOI":"10.1016\/j.bbcan.2022.188701","article-title":"Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors","volume":"1877","author":"Akbari","year":"2022","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05640-z","article-title":"The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies","volume":"103","author":"Zhang","year":"2024","journal-title":"Ann hematology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623610","article-title":"Therapeutic potential of TNF\u03b1 and IL1\u03b2 Blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009961","article-title":"A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome","volume":"7","author":"Jacobson","year":"2023","journal-title":"Blood advances"},{"key":"B140","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood-2023-187070","article-title":"Simvastatin with intrathecal dexamethasone reduces neurotoxicity in adults receiving chimeric antigen receptor (CAR) T-cells treatment","volume":"142","author":"Sumransub","year":"2023","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.jtct.2024.01.019","article-title":"Thrombotic microangiopathy following CAR-T cell therapy successfully treated with eculizumab in a pediatric patient","volume":"30","author":"Wheeler","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.08.009","article-title":"Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the\u00a0treatment of DLBCL","volume":"30","author":"Zhou","year":"2023","journal-title":"Mol Ther oncolytics"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13720","article-title":"Applications of single-cell omics for chimeric antigen receptor T cell therapy","volume":"171","author":"Ghaffari","year":"2024","journal-title":"Immunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1699894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:23:08Z","timestamp":1762150988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1699894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":144,"alternative-id":["10.3389\/fimmu.2025.1699894"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1699894","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1699894"}}